Glutamaterge Substanzen in der Behandlung von Zwanghaftigkeit und Impulsivität in der Kinder- und Jugendpsychiatrie

• Verfasst von: Mechler, Konstantin [VerfasserIn]
• Verfasst von: Banaschewski, Tobias [VerfasserIn]
• Verfasst von: Dittmann, Ralf [VerfasserIn]
• Titel: Glutamaterge Substanzen in der Behandlung von Zwanghaftigkeit und Impulsivität in der Kinder- und Jugendpsychiatrie
• Titelzusatz: eine systematische Übersichtsarbeit
• Verf.angabe: Konstantin Mechler, Alexander Häge, Nina Schweinfurth, Jeffrey C. Glennon, Rick M. Dijkhuizen, Declan Murphy, Sarah Durston, Steven Williams, Jan K. Buitelaar, Tobias Banaschewski, Ralf W. Dittmann and the TACTICS Consortium
• Jahr: 2018
• Jahr des Originals: 2017
• Umfang: 18 S.
• Fussnoten: Available online: September 18, 2017 ; Gesehen am 19.09.2018
• Titel Quelle: Enthalten in: Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie
• Ort Quelle: Bern : Huber, 1999
• Jahr Quelle: 2018
• Band/Heft Quelle: 46(2018), 3, Seite 246-263
• ISSN Quelle: 1664-2880
• DOI: doi:10.1024/1422-4917/a000546
• Datenträger: Online-Ressource
• Sprache: ger
• K10plus-PPN: 158110023X

Abstract

Objective: Research has implicated glutamatergic projections between the various frontal subregions in the pathogenesis of compulsivity and impulsivity. Reducing striatal glutamate release, or antagonising the action of glutamate at its receptors, may therefore represent viable treatment strategies. Several glutamatergic agents with regulatory approval for other indications are available and may be of potential benefit in the treatment of compulsivity/impulsivity in psychiatric disorders in paediatric patients. Method: This review was performed according to PRISMA guidelines and evaluates available scientific literature concerning the use of glutamatergic agents in these patients, in order to determine their reported effectiveness/efficacy and tolerability/safety. Results: Out of a total of 1,426 publications, 21 trials examining six glutamatergic substances in patients with obsessive-compulsive disorder, autism spectrum disorders, and attention deficit/hyperactivity disorder were included. Conclusions: Trial designs as well as results were heterogeneous and thus comparability was limited. Available data support the hypothesis that glutamatergic agents are of potential value in the treatment of compulsivity/impulsivity in children and adolescents. Based on the data reviewed, memantine and N-acetylcysteine suggest the best risk-benefit profile for future trials. Riluzole should primarily be further investigated in adults. Clinical research of this nature is a key element of the TACTICS Consortium project funded by the European Union (FP7).